MSLN and Miyoshi myopathy: One of the most extensively studied blood-based biomarkers is soluble mesothelin-related peptides (SMRP); however, the poor sensitivity limits its added value to early diagnosis.10,11 Nevertheless, the results of our previous study suggest that SMRP may be a useful tumour marker for detecting the progression of MM and evaluating tumour response to treatment.12